ME00601B - Facteur viii modifie - Google Patents

Facteur viii modifie

Info

Publication number
ME00601B
ME00601B MEP-2009-82A MEP8209A ME00601B ME 00601 B ME00601 B ME 00601B ME P8209 A MEP8209 A ME P8209A ME 00601 B ME00601 B ME 00601B
Authority
ME
Montenegro
Prior art keywords
factor viii
modified factor
modified
hemophilia
devoid
Prior art date
Application number
MEP-2009-82A
Other languages
English (en)
Unknown language (me)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MEP8209A publication Critical patent/MEP8209A/xx
Publication of ME00601B publication Critical patent/ME00601B/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MEP-2009-82A 2000-03-10 2001-02-16 Facteur viii modifie ME00601B (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (fr) 2000-03-10 2001-02-16 Facteur viii modifie

Publications (2)

Publication Number Publication Date
MEP8209A MEP8209A (en) 2011-12-20
ME00601B true ME00601B (fr) 2011-12-20

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-82A ME00601B (fr) 2000-03-10 2001-02-16 Facteur viii modifie

Country Status (36)

Country Link
US (3) US6458563B1 (fr)
EP (1) EP1280540B1 (fr)
JP (1) JP4044337B2 (fr)
KR (1) KR100485525B1 (fr)
CN (1) CN1191360C (fr)
AT (1) ATE391512T1 (fr)
AU (2) AU3841601A (fr)
BE (1) BE2016C024I2 (fr)
BR (2) BR122013026957A8 (fr)
CA (1) CA2400295C (fr)
CY (2) CY1108179T1 (fr)
CZ (1) CZ298250B6 (fr)
DE (1) DE60133541T2 (fr)
DK (1) DK1280540T3 (fr)
EE (1) EE05075B1 (fr)
ES (1) ES2304379T3 (fr)
FR (1) FR16C0016I2 (fr)
HK (1) HK1051004A1 (fr)
HU (2) HU227804B1 (fr)
IL (2) IL151371A0 (fr)
LT (1) LTC1280540I2 (fr)
LU (1) LU93049I2 (fr)
ME (1) ME00601B (fr)
MX (1) MXPA02008798A (fr)
NL (1) NL300808I2 (fr)
NO (2) NO331935B1 (fr)
NZ (1) NZ520799A (fr)
PL (1) PL202936B1 (fr)
PT (1) PT1280540E (fr)
RS (1) RS50364B (fr)
RU (1) RU2285724C2 (fr)
SI (1) SI1280540T1 (fr)
SK (1) SK286205B6 (fr)
UA (1) UA75064C2 (fr)
WO (1) WO2001068109A1 (fr)
ZA (1) ZA200206810B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
CA2434097A1 (fr) * 2001-01-12 2002-08-08 The American National Red Cross Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
JP4634036B2 (ja) * 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005017149A1 (fr) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
ATE368687T1 (de) * 2003-06-26 2007-08-15 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (fr) * 2003-12-03 2013-04-16 University Of Rochester Facteur viii recombine presentant une activite specifique amelioree
ES2449044T3 (es) * 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
WO2005123928A1 (fr) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production du facteur viii de coagulation humain à partir de cellules végétales et de plantes entières
EP3153181A1 (fr) * 2004-11-12 2017-04-12 Bayer HealthCare LLC Modification dirigée sur site de fviii bdd
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
KR101492422B1 (ko) * 2006-04-11 2015-02-12 체에스엘 베링 게엠베하 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
EP1935430A1 (fr) * 2006-12-22 2008-06-25 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (fr) * 2007-05-04 2008-11-05 Novo Nordisk A/S Amélioration des titres de polypeptide de facteur VIII dans les cultures cellulaires
CA2703948A1 (fr) 2007-11-01 2009-05-07 University Of Rochester Facteur viii recombinant ayant une stabilite accrue
EP2149603A1 (fr) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
WO2010091122A1 (fr) 2009-02-03 2010-08-12 Amunix, Inc. Polypeptides recombinants étendus et compositions les comprenant
EP2440239B1 (fr) 2009-06-09 2017-09-13 Prolong Pharmaceuticals, LLC Compositions d'hémoglobine
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
WO2011060371A2 (fr) * 2009-11-13 2011-05-19 Puget Sound Blood Center Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
LT2506868T (lt) 2009-12-06 2018-02-26 Bioverativ Therapeutics Inc. Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
PL2591006T3 (pl) 2010-07-09 2019-10-31 Bioverativ Therapeutics Inc Przetwarzalne cząsteczki jednołańcuchowe i polipeptydy wytworzone przy ich zastosowaniu
EP2591101B1 (fr) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systèmes pour le traitement du facteur viii et procédés associés
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
EA201370151A1 (ru) * 2011-01-05 2013-11-29 Экспрешен Терапетикс, Ллс Высокопродуктивная суспензионная клеточная линия, система и способ ее получения
EP2717898B1 (fr) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Composés pro-coagulants et leurs procédés d'utilisation
CA2841066C (fr) 2011-07-08 2023-09-26 Biogen Idec Hemophilia Inc. Polypeptides chimeriques et hybrides du facteur viii et leurs procedes d'utilisation
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
WO2013106787A1 (fr) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Facteur viii chimérique et polypeptides et leurs utilisations
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
CA2875246A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Composes pro-coagulants
EP2870250B2 (fr) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (fr) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Procédé d'utilisation de polypeptide du facteur viii
EP2928303A4 (fr) 2012-12-07 2016-07-13 Haplomics Inc Réparation de la mutation du facteur viii et induction de la tolérance
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP4122487A1 (fr) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3060242A1 (fr) 2013-10-22 2016-08-31 DBV Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP2881463A1 (fr) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
IL282168B2 (en) 2014-01-10 2023-03-01 Bioverativ Therapeutics Inc Factor viii chimeric proteins and their uses
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
EP3107561A4 (fr) * 2014-02-19 2017-12-20 Bloodworks Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
WO2015132724A1 (fr) 2014-03-05 2015-09-11 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
CN116949052A (zh) 2015-11-13 2023-10-27 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
EP3374388A1 (fr) 2015-11-13 2018-09-19 Baxalta Incorporated Vecteurs viraux codant pour des variants du facteur viii de recombinaison avec une expression augmentée pour la thérapie génique de l'hémophilie a
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
WO2017222337A1 (fr) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US11633504B2 (en) 2017-05-09 2023-04-25 Emory University Nucleic acids encoding clotting factor variants and their use
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
BR112021000695A2 (pt) 2018-07-16 2021-04-20 Baxalta Incorporated métodos para tratar hemofilia a e para monitorar a eficácia da terapia gênica de fator viii de hemofilia a.
CN113227385A (zh) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
WO2020257586A2 (fr) 2019-06-20 2020-12-24 Baxalta Incorporated Méthode de traitement avec une thérapie génique à base de virus
JP2023506171A (ja) 2019-12-12 2023-02-15 武田薬品工業株式会社 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
US11906532B2 (en) 2021-03-31 2024-02-20 Haemonetics Corporation Hemostasis measurement device quality control formulations
EP4355768A1 (fr) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
CN118019758A (zh) 2021-09-30 2024-05-10 比奥维拉迪维治疗股份有限公司 编码免疫原性降低的因子viii多肽的核酸
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (fr) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production de facteur VIII et produits apparentés
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues de polypeptides du facteur viii:c comprenant des domaines ou des sous-domaines du facteur v
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
ZA200206810B (en) 2003-11-26
EP1280540A1 (fr) 2003-02-05
AU3841601A (en) 2001-09-24
DK1280540T3 (da) 2008-07-14
CZ20023346A3 (cs) 2003-01-15
CA2400295A1 (fr) 2001-09-20
PL202936B1 (pl) 2009-08-31
US20030068785A1 (en) 2003-04-10
LU93049I2 (fr) 2016-06-27
SK286205B6 (sk) 2008-05-06
NO20024296L (no) 2002-11-08
NZ520799A (en) 2004-06-25
RU2002124123A (ru) 2004-03-27
HK1051004A1 (en) 2003-07-18
IL151371A (en) 2010-12-30
BRPI0109131B1 (pt) 2020-08-25
IL151371A0 (en) 2003-04-10
SI1280540T1 (sl) 2008-08-31
YU68002A (sh) 2005-11-28
LTC1280540I2 (lt) 2020-05-25
PL359672A1 (en) 2004-09-06
FR16C0016I1 (fr) 2016-04-29
US7122634B2 (en) 2006-10-17
CN1416348A (zh) 2003-05-07
NO2016007I1 (no) 2016-05-10
FR16C0016I2 (fr) 2018-11-02
CY1108179T1 (el) 2014-02-12
BE2016C024I2 (fr) 2020-01-30
NL300808I1 (fr) 2016-05-18
SK14392002A3 (sk) 2003-06-03
NO331935B1 (no) 2012-05-07
MXPA02008798A (es) 2003-04-25
JP2003526358A (ja) 2003-09-09
CA2400295C (fr) 2012-01-10
EP1280540A4 (fr) 2004-11-03
HU227804B1 (en) 2012-03-28
BR122013026957A2 (fr) 2004-12-07
DE60133541T2 (de) 2009-05-07
MEP8209A (en) 2011-12-20
KR20020081426A (ko) 2002-10-26
CN1191360C (zh) 2005-03-02
EE05075B1 (et) 2008-10-15
US7012132B2 (en) 2006-03-14
NO2016007I2 (no) 2016-05-10
WO2001068109A1 (fr) 2001-09-20
EE200200510A (et) 2004-02-16
UA75064C2 (en) 2006-03-15
KR100485525B1 (ko) 2005-04-28
US20050079584A1 (en) 2005-04-14
CY2016011I2 (el) 2016-10-05
PT1280540E (pt) 2008-06-09
ATE391512T1 (de) 2008-04-15
ES2304379T3 (es) 2008-10-16
DE60133541D1 (de) 2008-05-21
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
RS50364B (sr) 2009-11-10
AU2001238416B2 (en) 2004-09-02
NL300808I2 (nl) 2020-12-21
HUP0300586A3 (en) 2006-11-28
BRPI0109131B8 (pt) 2021-07-06
EP1280540B1 (fr) 2008-04-09
CY2016011I1 (el) 2016-10-05
BR0109131A (pt) 2004-12-07
HUS1600020I1 (hu) 2016-06-28
US6458563B1 (en) 2002-10-01
HUP0300586A2 (hu) 2003-06-28
BR122013026957A8 (pt) 2017-02-21
JP4044337B2 (ja) 2008-02-06
CZ298250B6 (cs) 2007-08-01

Similar Documents

Publication Publication Date Title
ME00601B (fr) Facteur viii modifie
EE05158B1 (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
DE60018372D1 (de) Oralzusammensetzung als mikroemulsion von silybin
ATE330017T1 (de) Kallikrein gen
SE9901077D0 (sv) Novel use
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
DE60034249D1 (de) Kombination enthaltend cyamemazine und ein atypisches neuroleptikum
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
DE50307013D1 (de) Verwendung von hexenal-derivaten als riechstoffe
ECSP003832A (es) Composiciones farmaceuticas